Table 2.
Clinical characteristics of the SCOT participants at randomization
| Characteristics | Immunosuppressive treatment naïve | Immunosuppressive treatment exposed | Total |
|---|---|---|---|
| Participants, n | 14 | 57 | 71 |
| Age, years, median (minimum–maximum) | 44 (30–56) | 47 (22–65) | 47 (22–65) |
| Sex (male/female), n | 3/11 | 23/34 | 26/45 |
| Race (Caucasian/Black/Asian/Other), n | 12/1/0/1 | 46/5/3/3 | 58/6/3/4 |
| Disease duration between first non-Raynaud’s symptom and randomization, years, median (minimum–maximum) | 1.9 (0.9–4.1) | 1.8 (0.5–5.4) | 1.8 (0.5–5.4) |
| mRSS, median (minimum–maximum) | 23(8–37) | 30 (12–49)b | 29 (8–49) |
| FVC, % predicted, median (minimum–maximum) | 74 (53–96) | 74 (36–107) | 74 (36–107) |
| DLCO, % predicteda, median (minimum–maximum) | 51.4 (41.0–67.8) | 54.2 (40.2–70.0) | 53.1 (40.2–70.0) |
| Hemoglobin, g/dL, median (minimum–maximum) | 12.9 (8.7–14.1) | 12.1 (8.6–15.1) | 12.3 (8.6–15.1) |
| ESR in 1 h, median (minimum–maximum) | 19.0 (5.0–60.0) | 24.0 (3.0–108.0) | 22.0 (3.0–108.0) |
| Creatinine clearance, mL/min/1.73 m2, median (minimum–maximum) | 113.5 (33.6–197.0) | 122.0 (25.0–305.6) | 117.8 (25.0–305.6) |
a
Corrected for altitude and hemoglobin.
b
The unadjusted P-value for the Mann–Whitney statistic to compare groups = 0.027. No other P-values are <0.05.